adalimumab


Also found in: Medical, Wikipedia.

ad·a·lim·u·mab

 (ăd′ə-lĭm′o͞o-măb′)
n.
A human monoclonal antibody that blocks the action of tumor necrosis factor and is used to treat certain autoimmune disorders, especially rheumatoid arthritis, Crohn's disease, and psoriasis.
Translations

adalimumab

n adalimumab m
References in periodicals archive ?
the subject matter of the public procurement is the continuous supply of medicinal products with adalimumab for the needs of the central military hospital - military university hospital prague (hereinafter referred to as the "central contracting authority" or "icn"), The military hospital olomouc (hereinafter referred to as " vnol ") in accordance with the terms and conditions.
M2 PHARMA-February 22, 2018-Celltrion Healthcare Study Shows Infliximab Biosimilar CT-P13 is Comparable to Reference Infliximab and Adalimumab
M2 EQUITYBITES-January 17, 2018-Sandoz submits proposed biosimilar adalimumab BLA with the US FDA for treating immunological diseases
Cyltezo is an injectable tumor necrosis factor blocker, and is a biosimilar to adalimumab (Humira).
The National Institute for Health and Care Excellence (NICE) has issued guidance recommending the use of adalimumab for the treatment of noninfectious uveitis.
Earlier this year, Amgen won European approval for the first copy of Humira, also called adalimumab.
LAS VEGAS -- Adalimumab proved no better than placebo for the treatment of erosive hand osteoarthritis in the double-blind, placebo-controlled, randomized HUMOR trial, throwing cold water on hopes that a disease-modifying treatment for osteoarthritis might at long last have been found.
Methods: Serum levels of adalimumab and anti-drug antibodies (ADAs) were measured in 19 patients with psoriasis.
Regarding the impact of these facts on clinical decision and the importance of the choice of first biologic agents in everyday clinical practice, several years ago, we decided to implement specific practice to prescribe adalimumab preferably as the first anti-tumor necrosis factor (TNF) agent in all ANA positive oligoarticular/ extended oligoarticular and ERA JIA patients with associated uveitis at our center.
The two medicines are the first adalimumab biosimilars that have been recommended for approval in the European Union.
today announced the additional approval for a new indication of HUMIRA (generic name: adalimumab [recombinant]), a fully human anti-TNF-alha monoclonal antibody formulation, in the treatment of non-infectious intermediate, posterior and panuveitis.
The AURIEL-Psoriasis (PsO) study is a randomized, double-blind, active-controlled trial evaluating the efficacy, safety and immunogenicity of Merck KGaA's adalimumab biosimilar candidate MSB11022 compared with AbbVie's Humira (adalimumab) in patients with moderate to severe chronic plaque psoriasis.